New SIMCA 16 software for multivariate data analytics
Makes model data easier to interpret for better process control.
Sartorius Stedim Biotech (SSB) has announced the new SIMCA 16 software for multivariate data analytics is available from its subsidiary Sartorius Stedim Data Analytics. The updated SIMCA focuses on delivering a complete data analysis experience, from data organization through to data-driven decision making, supported by multivariate models for single and multiblock analysis.
The new SIMCA 16 software has enhanced functionality features which will save time for expert users, as well as those new to multivariate data analysis. Usability improvements provide novices with an intuitive introduction to SIMCA and existing users with superior plot interactivity and quick raw data visualization capabilities. The software’s updated graphical interface with its context-based ribbons and panes means scientists will spend less time looking for functions and the new ribbons will be especially useful for those working with batch data. The new data analytics software also includes a wizard that adapts to users’ modelling objectives (rather than focusing on which algorithm to use) and guides them through set-up, making the initial steps of creating each model easier. Additionally, its advanced data merging functionality saves time by eliminating the need to manually combine and align data in Excel.
To make pattern data in models easier to interpret and use, SIMCA 16 comes with novel score space exploration and multivariate solver tools which help turn models into real-life factor combinations. In just one click, the score space exploration tool allows users to convert scatter plots into real factor settings to, for example, detect which sample is missing in a stack of observations. With the multivariate solver tool, scientists can determine optimum factor settings for desired process outputs such as Critical Quality Attributes and can also lock model parameters to a specific batch of raw material to find the process parameters for achieving consistent product quality and operational efficiency. Both tools make trouble shooting process data and performing deviation analysis simpler tasks.
To increase application and functional flexibility, SIMCA 16 includes MOCA, a novel tool for analyzing more than two blocks of data and new Python plugin capability. MOCA provides a quick overview of an entire system, delivering invaluable information for continuing analysis, and is ideal for scientists such as systems biologists wanting to compare data from one system that has been obtained using different “omics” and other techniques.
The Python plugin functionality in SIMCA 16 provides greater workflow flexibility by enabling users to create a file reader plugin which can read files like any other file format as they are being imported. This is especially useful when scientists need to transfer data from a new instrument with a non-standard export format or from text files where data is not configured correctly for SIMCA, saving them time and effort with pre-processing and importing data.
“Developing and producing biotherapeutics generates a vast array of process data in different formats from a variety of equipment types. This data holds the key to improving performance but can be challenging to input, model and interpret,” said Stefan Rännar, Product Manager at Sartorius Stedim Data Analytics. “We’re pleased to introduce our new SIMCA® 16 because it offers elevated levels of control over data, model generation and decision making, enabling scientists to optimize resource use and cost efficiency, while more importantly, achieving consistency in their product quality,” he added.
The use of SIMCA is recognized by the EMA and US FDA for Real-Time Release testing and the SIMCA® 16 software have been developed and extensively tested and validated for use in a highly-regulated environment.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance